JP5165827B2 - 卵巣腫瘍および子宮内膜腫瘍に対するl1接着分子に基づく卵巣腫瘍または子宮内膜腫瘍の検出方法 - Google Patents

卵巣腫瘍および子宮内膜腫瘍に対するl1接着分子に基づく卵巣腫瘍または子宮内膜腫瘍の検出方法 Download PDF

Info

Publication number
JP5165827B2
JP5165827B2 JP2002509771A JP2002509771A JP5165827B2 JP 5165827 B2 JP5165827 B2 JP 5165827B2 JP 2002509771 A JP2002509771 A JP 2002509771A JP 2002509771 A JP2002509771 A JP 2002509771A JP 5165827 B2 JP5165827 B2 JP 5165827B2
Authority
JP
Japan
Prior art keywords
tumor
antibody
ovarian
endometrial
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002509771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004513074A5 (cg-RX-API-DMAC7.html
JP2004513074A (ja
Inventor
アルテフォグト,ペーター
フォゲル,ミナ
Original Assignee
ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ
モア リサーチ アプリケイションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ, モア リサーチ アプリケイションズ リミテッド filed Critical ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ
Publication of JP2004513074A publication Critical patent/JP2004513074A/ja
Publication of JP2004513074A5 publication Critical patent/JP2004513074A5/ja
Application granted granted Critical
Publication of JP5165827B2 publication Critical patent/JP5165827B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2002509771A 2000-07-10 2001-07-10 卵巣腫瘍および子宮内膜腫瘍に対するl1接着分子に基づく卵巣腫瘍または子宮内膜腫瘍の検出方法 Expired - Fee Related JP5165827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00114788A EP1172654B1 (en) 2000-07-10 2000-07-10 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
EP00114788.3 2000-07-10
PCT/EP2001/007924 WO2002004952A2 (en) 2000-07-10 2001-07-10 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors

Publications (3)

Publication Number Publication Date
JP2004513074A JP2004513074A (ja) 2004-04-30
JP2004513074A5 JP2004513074A5 (cg-RX-API-DMAC7.html) 2008-09-04
JP5165827B2 true JP5165827B2 (ja) 2013-03-21

Family

ID=8169210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002509771A Expired - Fee Related JP5165827B2 (ja) 2000-07-10 2001-07-10 卵巣腫瘍および子宮内膜腫瘍に対するl1接着分子に基づく卵巣腫瘍または子宮内膜腫瘍の検出方法

Country Status (10)

Country Link
US (2) US7618785B2 (cg-RX-API-DMAC7.html)
EP (2) EP1172654B1 (cg-RX-API-DMAC7.html)
JP (1) JP5165827B2 (cg-RX-API-DMAC7.html)
CN (1) CN1479871A (cg-RX-API-DMAC7.html)
AT (1) ATE377192T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001285820A1 (cg-RX-API-DMAC7.html)
CA (1) CA2415364C (cg-RX-API-DMAC7.html)
DE (1) DE60036935T2 (cg-RX-API-DMAC7.html)
ES (1) ES2296586T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002004952A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US6852874B2 (en) 2000-10-02 2005-02-08 The Scripps Research Institute Second cycle asymmetric dihydroxylation reaction
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
AU2007288620B2 (en) 2006-08-23 2012-08-30 Korea Research Instititute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
WO2008151819A2 (en) * 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) 2008-11-27 2010-06-07 한국생명공학연구원 L1cam의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101504039B1 (ko) * 2012-11-16 2015-03-19 강원대학교산학협력단 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR20250140647A (ko) * 2020-08-03 2025-09-25 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1399850A2 (en) * 2001-02-21 2004-03-24 The Board of Regents of The University of Oklahoma Hla ligand database utilizing predictive algorithms and methods of making and using same

Also Published As

Publication number Publication date
US7670601B2 (en) 2010-03-02
CA2415364C (en) 2009-02-24
WO2002004952A2 (en) 2002-01-17
DE60036935T2 (de) 2008-08-21
AU2001285820A1 (en) 2002-01-21
CA2415364A1 (en) 2002-01-17
EP1172654A1 (en) 2002-01-16
DE60036935D1 (de) 2007-12-13
US7618785B2 (en) 2009-11-17
EP1172654B1 (en) 2007-10-31
ES2296586T3 (es) 2008-05-01
JP2004513074A (ja) 2004-04-30
EP1386162A2 (en) 2004-02-04
CN1479871A (zh) 2004-03-03
ATE377192T1 (de) 2007-11-15
WO2002004952A3 (en) 2003-11-06
US20080138331A1 (en) 2008-06-12
US20040259084A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US7670601B2 (en) Diagnostic and therapeutic methods based on the L1 adhesion molecule for ovarian and endometrial tumors
Miyake et al. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer
US8486648B2 (en) Methods of detecting ovarian cancer
US20160153996A1 (en) B7-h1 and b7-h4 in cancer
JP5265140B2 (ja) 卵巣癌の検出方法及び検出用キット
WO2011003369A1 (zh) 一种新的肿瘤标志物
WO2005052156A1 (ja) 肝癌の検出方法及び肝癌診断薬並びに癌治療薬
EP0753011B1 (en) Thymidine kinase tk1, peptide, corresponding antibodies and use of these in determination of tumor proliferation
JP4452839B2 (ja) Cxcr3阻害剤を含有する医薬組成物
CA2495849A1 (en) Ptk7 protein involvement in carcinoma
WO2001085762A2 (en) Cancer diagnosis and assays for screening anti-cancer agents
JP6537095B2 (ja) 癌の再発及び/又は転移の予測診断用マーカー
US20020146702A1 (en) Nucleic acid molecule associated with prostate cancer and melanoma immunodetection and immunotherapy
US7928188B2 (en) Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer
JP5562738B2 (ja) 子宮体部類内膜腺癌の予後判定方法
JP2005162714A (ja) グリシンnメチルトランスフェラーゼモノクローナル抗体およびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121220

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5165827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees